NASDAQ:OTIC - Otonomy Stock Price, Forecast & News

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Otonomy Inc (NASDAQ:OTIC) released its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.45) by $0.12. The biopharmaceutical company earned $0.13 million during the quarter, compared to analysts' expectations of $0.31 million. Otonomy had a negative net margin of 6,516.78% and a negative return on equity of 72.06%. View Otonomy's Earnings History.

Otonomy is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Otonomy.

4 equities research analysts have issued 1 year price objectives for Otonomy's shares. Their forecasts range from $5.00 to $8.00. On average, they expect Otonomy's stock price to reach $7.00 in the next year. This suggests a possible upside of 118.8% from the stock's current price. View Analyst Price Targets for Otonomy.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Otonomy.

Press coverage about OTIC stock has trended somewhat negative recently, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Otonomy earned a news impact score of -1.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Otonomy.

Otonomy saw a increase in short interest in December. As of December 13th, there was short interest totalling 131,200 shares, an increase of 5.2% from the November 28th total of 124,700 shares. Based on an average trading volume of 99,000 shares, the short-interest ratio is presently 1.3 days. Currently, 0.5% of the company's stock are short sold. View Otonomy's Current Options Chain.

Some companies that are related to Otonomy include Catalyst Pharmaceuticals (CPRX), ProQR Therapeutics (PRQR), Mirum Pharmaceuticals (MIRM), Avedro (AVDR), Progenics Pharmaceuticals (PGNX), Xenon Pharmaceuticals (XENE), Fulcrum Therapeutics (FULC), Avid Bioservices (CDMO), Merus (MRUS), DURECT (DRRX), Urovant Sciences (UROV), MannKind (MNKD), AnaptysBio (ANAB), Verrica Pharmaceuticals (VRCA) and Kindred Biosciences (KIN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Corbus Pharmaceuticals (CRBP), Catabasis Pharmaceuticals (CATB), Melinta Therapeutics (MLNT), Novavax (NVAX), Intercept Pharmaceuticals (ICPT), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX), ACADIA Pharmaceuticals (ACAD), Strongbridge Biopharma (SBBP) and Spectrum Pharmaceuticals (SPPI).

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OTIC stock can currently be purchased for approximately $3.20.

Otonomy has a market capitalization of $98.40 million and generates $750,000.00 in revenue each year. The biopharmaceutical company earns $-50,370,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Otonomy employs 49 workers across the globe.View Additional Information About Otonomy.

The official website for Otonomy is http://www.otonomy.com/.

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]